NCT05176470View on ClinicalTrials.gov

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Locally Advanced MelanomaPathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8Stage IV Melanoma
Interventions
DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine

Given IV

BIOLOGICAL

Lifileucel

Given by IV infusion

BIOLOGICAL

Pembrolizumab

Given IV

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgery

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

Sponsors
All Listed Sponsors
collaborator

Iovance Biotherapeutics, Inc.

INDUSTRY

lead

Richard Wu

OTHER